BioMarin Pharmaceutical (NASDAQ:BMRN) traded today at a new 52-week high of $57.66. This new high was reached on approximately average trading volume as 905,000 shares traded hands, while the average 30-day volume is approximately 1.1 million shares.
In the past 52 weeks, shares of BioMarin Pharmaceutical have traded between a low of $31.91 and a high of $57.66 and are now at $56.56, which is 77% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.2% while the 50-day MA has advanced 1.3%.
There is potential upside of 4.2% for shares of BioMarin Pharmaceutical based on a current price of $56.56 and an average consensus analyst price target of $58.93. The stock should discover initial support at its 50-day moving average (MA) of $52.17 and subsequent support at its 200-day MA of $43.14.
BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin's subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology.